SCHEMBL2676144

SCHEMBL2676144

N#CCc1c(C(=O)O)c2cccc(Cl)c2c(=O)n1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 11/20 0.37
PIK3CG P48736 3/20 0.37
PIK3R1 P27986 6/20 0.36
PDE7A Q13946 1/20 0.36
RORC P51449 1/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
REN P00797 1/20 0.35
KMT2A Q03164 3/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CB P42338 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675943 0.84 PIK3CD (0.39) PIK3CDPIK3CGPIK3R1PDE7ARORC
SCHEMBL2676315 0.84 MAPK1 (0.47) ALDH1A1SMN1; SMN2KMT2ANPSR1L3MBTL1
SCHEMBL2675980 0.81 PIK3CD (0.39) PIK3CDPIK3CGPIK3R1PDE7ARORC
SCHEMBL2677117 0.80 THRB (0.40) PIK3CDPIK3CGRORCRENKMT2A
SCHEMBL2676814 0.79 PIK3CD (0.41) PIK3CDPIK3CGPIK3R1PDE7ARORC
SCHEMBL2677832 0.79 PIK3CD (0.43) PIK3CDPIK3CGPIK3R1RORCKMT2A
SCHEMBL2674631 0.78 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2RENKMT2AL3MBTL1
SCHEMBL1036361 0.78 RORC (0.51) PIK3CDPIK3CGRORCALDH1A1KMT2A
SCHEMBL2676864 0.76 CYP19A1 (0.42)
SCHEMBL1717623 0.76 TACR3 (0.48) PIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 PIK3CD 2379/4885PIK3CG 2438/4885PIK3R1 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.